Johnson & Johnson (JNJ) reported Q2 FY 2021 earnings of $2.48 per share (versus $1.67 per share in Q2 FY 2020), beating analysts’ consensus estimate of $2.29 per share.
The company’s quarterly revenues amounted to $23.312 bln (+27.1% y/y), beating analysts’ consensus estimate of $22.539 bln.
The company also issued raised guidance for FY 2021, projecting EPS of $9.60-9.70 versus its previous guidance of $9.42-$9.57 and analysts’ consensus estimate of $9.55 and revenues of $92.5-93.3 bln versus its previous guidance of $90.6-$91.6 bln and analysts’ consensus estimate of $92.55 bln.
JNJ rose to $170.50 (+1.22%) in pre-market trading.